JYNNEOS疫苗对确诊猴痘感染的有效性——纽约州,2022年
2022年纽约州除纽约市外报告375例猴痘病例,州卫生部门开展病例对照研究评估JYNNEOS疫苗有效性。252例病例与255例对照匹配分析显示,调整后1剂或2剂合并疫苗有效性为75.7%(95%CI=48.5%-88.5%),1剂为68.1%(95%CI=24.9%-86.5%),2剂为88.5%(95%CI=44.1%-97.6%)。
要点
- 调整后1剂或2剂JYNNEOS疫苗合并有效性为75.7%(95%CI=48.5%-88.5%)。
- 调整后1剂有效性为68.1%(95%CI=24.9%-86.5%)。
- 调整后2剂有效性为88.5%(95%CI=44.1%-97.6%)。
核心结论
- 研究结果支持按照CDC和纽约州卫生部门指南推荐接种2剂JYNNEOS疫苗。
研究设计与样本
- 纽约州卫生部门利用系统性监测报告数据开展病例对照研究,估计JYNNEOS疫苗对纽约市以外纽约州居民确诊猴痘的有效性。
- 病例定义为2022年7月24日至10月31日期间确诊猴痘的18岁及以上男性。
- 对照为同期确诊直肠淋病或一期梅毒、有男男性接触史且无猴痘的18岁及以上男性。
- 共纳入252例合格猴痘病例和255例对照,并与州免疫系统记录匹配。
- 采用条件logistic回归模型调整诊断周、地区、年龄和种族 ethnicity。
主要发现
- 调整后1剂(≥14天前接种)或2剂合并的疫苗有效性为75.7%(95%CI=48.5%-88.5%)。
- 调整后1剂疫苗有效性为68.1%(95%CI=24.9%-86.5%)。
- 调整后2剂疫苗有效性为88.5%(95%CI=44.1%-97.6%)。
关键数值与推荐
- JYNNEOS疫苗为FDA许可的2剂系列,两剂间隔4周。
- 疫苗有效性估计公式为1减去比值比(OR)乘以100。
临床怎么用
- 研究结果支持按照CDC和纽约州卫生部门指南推荐接种2剂JYNNEOS疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2022, an international Monkeypox virus outbreak, characterized by transmission primarily through sexual contact among gay, bisexual, and other men who have sex with men (MSM), resulted in 375 monkeypox (mpox) cases in the state of New York outside of New York City (NYC).*,† The JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic), licensed by the U.S. Food and Drug Administration (FDA) against mpox as a 2-dose series, with doses administered 4 weeks apart,§ was deployed in a national vaccination campaign.¶ Before this outbreak, evidence to support vaccine effectiveness (VE) against mpox was based on human immunologic and animal challenge studies (1-3). New York State Department of Health (NYSDOH) conducted a case-control study to estimate JYNNEOS VE against diagnosed mpox in New York residents outside of NYC, using data from systematic surveillance reporting. A case-patient was defined as a man aged ≥18 years who received a diagnosis of mpox during July 24-October 31, 2022. Contemporaneous control patients were men aged ≥18 years with diagnosed rectal gonorrhea or primary syphilis and a history of male-to-male sexual contact, without mpox. Case-patients and control patients were matched to records in state immunization systems. JYNNEOS VE was estimated as 1 - odds ratio (OR) x 100, and JYNNEOS vaccination status (vaccinated versus unvaccinated) at the time of diagnosis was compared, using conditional logistic regression models that adjusted for week of diagnosis, region, patient age, and patient race and ethnicity. Among 252 eligible mpox case-patients and 255 control patients, the adjusted VE of 1 dose (received ≥14 days earlier) or 2 doses combined was 75.7% (95% CI = 48.5%-88.5%); the VE for 1 dose was 68.1% (95% CI = 24.9%-86.5%) and for 2 doses was 88.5% (95% CI = 44.1%-97.6%). These findings support recommended 2-dose JYNNEOS vaccination consistent with CDC and NYSDOH guidance.
引用
- Rosenberg ES, Dorabawila V, Hart-Malloy R, et al. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37339074. doi:10.15585/mmwr.mm7220a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。